Cardiology

Endothelial to mesenchymal transition in the cardiogenesis and cardiovascular diseases.

Related Articles

Endothelial to mesenchymal transition in the cardiogenesis and cardiovascular diseases.

Curr Cardiol Rev. 2019 Aug 07;:

Authors: Anbara T, Sharifi M, Aboutaleb N

Abstract
Today cardiovascular diseases remain a leading cause of morbidity and mortality worldwide. Endothelial to mesenchymal transition (EndMT) does not only play a major role in the course of development but also contributes to several cardiovascular diseases in adulthood. EndMT is characterized by down-regulation of the endothelial proteins and highly up-regulated fibrotic specific genes and extracellular matrix-forming proteins. EndMT is also a transforming growth factor-β-driven (TGF-β) process in which endothelial cells lose their endothelial characteristics and acquire a mesenchymal phenotype with expression of α-smooth muscle actin (α-SMA), fibroblast-specific protein 1, etc. EndMT is a vital process during cardiac development, thus disrupted EndMT gives rise to the congenital heart diseases, namely septal defects and valve abnormalities. In this review, we have discussed the main signaling pathways mechanisms participating in the process of EndMT such as TGF-β and Bone morphogenetic protein (BMP), Wnt , and Notch signaling pathway and also studied the role of EndMT in physiological cardiovascular development and pathological conditions including myocardial infarction, pulmonary arterial hypertension, congenital heart defects, cardiac fibrosis, and atherosclerosis. As a perspective view, having a clear understanding of involving cellular and molecular mechanisms in EndMT and conducting Randomized controlled trials (RCTs) with a large number of samples for involving pharmacological agents may guide us into novel therapeutic approaches of congenital disorders and heart diseases.

PMID: 31393254 [PubMed – as supplied by publisher]

Source link




Related posts

Risk factors for heart failure in the community: differences by age and ejection fraction.

Newsemia

Heart attack: New finding may change the face of treatment

Newsemia

Patient Safety: Questions to Ask Your Health Care Provider

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy